natgillin/translations-raw huggingface dataset:
The method as claimed in claim 7 wherein data points in the driver profile are, for at least one profile index, classified against a plurality of possible values for the profile index, and wherein deriving the analysis profile comprises merging two or more possible values of the profile index. The method as claimed in claim 7 further comprising comparing the analysis profile to a reference profile. 
Postupak prema zahtjevima 8 ili 9, naznačen time da su podatkovne točke u vozačevom profilu, barem u jednom indeksiranom profilu, određene u odnosu na mnoštvo mogućih vrijednosti od indeksiranog profila i pri čemu deriviranje analitičkog profila sadrži spajanje dvije ili više moguće vrijednosti indeksiranog profila.
The method of claim 1, wherein the cell density is maintained at between 2.0×106 cells per mL and 4.0×106 per mL during the step of culturing the one or more mammalian cells. 
gustoću stanica se održava kod manje od 3,0 x 106 stanica po ml u koraku uzgoja jedne ili više stanica; ili
The compound of formula (I') of anyone of claims 12 to 15 for its use according to claim 12, wherein the inflammatory disease is one or more of rheumatoid arthritis; degenerative arthritis; and inflammatory diseases occurring from asthma, atopy, diabetes, or myocardial infarction. 
Spoj formule (I) iz bilo kojeg od patentnih zahtjeva 12 do 15 za njegovu primjenu prema patentnom zahtjevu 12, gdje je inflamatorna bolest jedna ili više od reumatoidnog artritisa; degenerativnog artritisa; i inflamatornih bolesti koje se javljaju kod astme, atopije, dijabetesa, ili infarkta miokarda.
a heavy chain having a heavy chain variable region comprising SEQ ID NO: 83, or an antigen-binding fragment thereof, and a light chain having a light chain variable region comprising SEQ ID NO: 84, or an antigen-binding fragment thereof; or 
Antitijelo ili antigen vezujući fragment istog prema zahtjevu 1, naznačen time da antitijelo obuhvaća laki lanac čiji je slijed SEQ ID NO: 44, i teški lanac čiji su sljedovi SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42 ili SEQ ID NO: 43.
The aqueous pharmaceutical suspension according to claim 3, wherein the benzyl alcohol is, by weight/volume (g/100 mL), 0.25% to 1.00%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što benzil-alkohol iznosi, težinski/volumno (£/100 ml otprilike 0,25 % do otprilike 1,00 %,
a high-pressure water gun, including a rain jet adjustment, (802), providing a jet of the above said solution on the road platform, where polluting functional liquids have been eventually lost by vehicles as a consequence of car accidents or breakdown; 
- - visokotlačnim vodenim topom, uključujući tuš-mlaznicu (802), koji daju mlaz gore navedene otopine na cestovnu plohu, gdje su zagađujuće funkcionalne tekućine eventualno bile prolivene iz vozila kao posljedica automobilskih nezgoda ili nesreća;
All publications, patents, patent applications and other references cited herein are hereby incorporated by reference. A method for treatment of an endogenous 11-cis-retinal deficiency in an eye of a human subject, the method comprising: 
HR P20140116 TI (D pri čemu A predstavlja CH2OR, a R tvori Tetinil ester, naznačena time, da je to upotreba za pripravu lijeka za liječenje endogene deficijencije 11-cis- retinala kod ljudskog subjekta.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and at least one compound selected from the group consisting of (B2) an azole fungicide. 
(A) spoja formule (I) naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) barem jednog spoja odabranog iz skupine koja se sastoji od (Bl) - strobilurin fungicida.
FIG. 2 shows the sheet metal strip on termination of the hole forming stage, 
prikazuje limenu metalnu traku na završetku faze oblikovanja rupa, slika 3
The pharmaceutical composition as claimed in claim 1, in which the agent comprises one or more components selected from the group consisting of: 
Farmaceutska kompozicija, koja sadrži jednu ili više komponenti izabranih iz grupe koju čine:
enabling control of the switch mode power conversion of the dimmer voltage (VΦ_DIM); 
omogućavanje kontrole pretvaranja snage napona (VΦ_DIM) dimera;
In this technique the winder unit is initially secured to the steering wheel side of the glazing panel, positioned above the steering wheel as shown in FIG. 9 . 
Jedinica za namatanje, namijenjena upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što je kolo za vođenje okretno pričvršćeno u odnosu na jedinicu.
A compound of formula (2): 
Spoj sa formulom (2):
A process according to claim 9 wherein step (i) comprises adding sodium hydride in a mixture of anhydrous dichloromethane and anhydrous THF to a mixture of said compound of formula Vb in anhydrous dichloromethane. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se korak (1) sastoji u dodavanju natrijevog hidrida u smjesi bezvodnog diklormetana s bezvodnim THF u smjesu navedenog spoja formule Vb u bezvodnom diklormetanu.
An isolated nucleic acid, said nucleic acid encoding the mutated PE of any one of claims 1 to 5. 
HR P20141236 T1 Izolirana nukleinska kiselina koja kodira mutirani PE iz bilo kojeg od zahtjeva 1 do 5.
The bispecific IgG antibody according to claim 6, wherein said mutated CH2 and/or lower hinge domains comprise at least one substitution at amino acids position 235 and/or 236 (numbering according to Kabat). 
Bispecifično IgG protutijelo sukladno patentnom zahtjevu 6, naznačeno time što navedeni mutirani CH2 i/ili niže zglobne domene sadrže najmanje jednu supstituciju na aminokiselinskom položaju 235 i/ii 236 (numercija sukladno Kabat-u).
The formulation as defined in Claim 3 in the form of a 10 mg tablet coanprising: 
Formulacija kako je definirana u patentnom zahtjevu 1 u obliku tablete koja sadrži:
The 32nd item relates to a floor panel according to the 31st item, characterized in that the attachment portion (50) consists of an attachment body which, viewed in cross-section, extends in a flat or rather flat direction and which is provided in a recess (13). 
Podni panel prema patentnom zahtjevu 4, naznačen time što se spojni dio (50) sastoji od spojnog elementa koji se gledan u presjeku, pruža u ravnom ili otprilike ravnom smjeru i koji je u udubljenju (13).
The method of claim 15, wherein the dose is a twice-daily dose of a) a metered nominal dose of aclidinium equivalent to 400 micrograms plus/minus 10% of aclidinium bromide, b) an emitted dose of aclidinium equivalent to 360 micrograms plus/minus 35% aclidinium bromide, or c) a fine particle dose of aclidinium equivalent to 120 micrograms plus/minus 35% aclidinium bromide. 
Primjena aklidinija u slobodnom obliku ili u obliku farmaceutski prihvatljive soli u proizvodnji lijeka za liječenje kronične opstruktivne plućne bolesti u bolesnika kojem je potrebno takvo liječenje, pri čemu se spomenuta primjena sastoji od davanja inhalacijom jednom ili dvaput dnevno odmjerene nominalne doze aklidinija jednake 400 mikrograma (plus/minus 10 %) aklidinijevog bromida.
The isolated solid was recrystalized from hot EtOAc/hexane (2:1) to give the title compound as white crystals (4.15 g, 70% yield). 
Izolirana čvrsta supstanca je rekristalizirana iz vrelog FtOAc/heksana (2:1) da bi se dobio spoj iz naslova u obliku bijelih kristala (4.15 g, 70% prinos).
The method of claim 30, wherein the method comprises administering two oral doses of a safe and effective amount of the human live attenuated rotavirus composition to an infant within 4-15 weeks of age at the time of dose 1. 
Upotreba u skladu s patentnim zahtjevom 33, naznačena time što se navedeno liječenje ili sprječavanje sastoji u primjeni dvije oralne doze sigurne i djelotvorne količine pripravka živog oslabljenog ljudskog totavirusa na dojenčetu unutar 4-15 tjedana starosti u vrijeme 1. doze.
A clear solution is prepared from 4 grams of polyethylene glycol 400 and 4 grams of poloxamer 188. 
Pripremi se bistra otopina od 4 grama polietilen glikola 400 i 4 grama poloksamera 188.
applying first and second adhesive portions (102,104) onto a first surface (106) of the napkin; and 
Uređaj prema zahtjevu 1, gdje nanošenje navedenog ljepila znači raspršivanje navedenog ljepila na navedenu prvu površinu (106).
wherein the pharmacokinetic parameter tmax is within the range of from 0.5 to 16 h, for use in the treatment of nociceptive pain. 
pri čemu je farmakokinetički parametar tax, izražen kao srednja vrijednost u rasponu od 0,5 do 16 h, naznačen time što je za uporabu za liječenje nociceptivne boli, pri čemu se farmaceutski oblik doziranja primjenjuje oralno jednom dnevno.
Such a vial or syringe can be filled using a hollow needle passed through the closure part or plunger respectively, the needle is then withdrawn, and the small residual puncture hole in the closure or plunger may then be sealed by heat sealing, e.g. using a focused laser beam. 
Takva bočica ili šprica može biti napunjena tako da se upotrebi šuplja igla koja prolazi kroz element za zatvaranje, odnosno kroz klip, pri čemu se nakon toga igla izvuče, a mala preostala probušena rupica u zatvaraču ili u klipu može tada biti nepropusno zatvorena pomoću vrućeg nepropusnog zatvaranja, na primjer, korištenjem fokusiranog laserskog snopa.
Consequently, inhibition of this receptor activation prevents the intracellular calcium increase and leads to smooth muscle relaxation. 
Dosljedno tome, inhibicija aktivacije ovog receptora sprječava povećanje unutarstaničnog kalcija i dovodi do opuštanja glatkih mišića.
An isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide is selected from the group consisting of peptides comprising the amino acid sequence of SEQ ID NO: 30, 19, 22, 34, or 358. 
Peptid s manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed SEQ ID NO: 194, 174, 178 ili 186.
The TCR or cell for use of claim 18, wherein the method comprises adoptive therapy. 
TCR ili stanica za uporabu sukladno patentnom zahtjevu 14, pri čemu postupak sadrži adoptivnu terapiju.
The insertion of transformer 300 can be performed on conductor 12 as well, or downstream of relay 20; the primary winding of such transformer 300 is the conductor 14 itself while the secondary, centered-tapped, is realized by means of a second winding 330. 
Transformator 300 se može dodati i na otpornik 12, ili niže od releja 20; primarni namot transformatora 300 je tada sam vodič 14, dok je sekundarni, podijeljen na dva dijela (klizačem), ostvaren drugim namotom 330.
A compound or a pharmaceutically acceptable salt of said compound, said compound having the structure: 
navedenog spoja, naznačen time što navedeni spoj ima strukturu:
Unless the context requires otherwise, a reference in this application to dihydrotetrabenazine and its isomers, includes within its scope not only the free base of the dihydrotetrabenazine but also its salts, and in particular acid addition salts. 
Ukoliko kontekst ne zahtjeva drugačije, reference u ovoj prijavi koje se odnose na Izomer A uključuju unutar dosega prijave ne samo slobodne baze dihidrotetrabenazina već također i njegove soli, te posebno kiselinske adicijske soli.
In some embodiments, the disorder or disease is osteoarthritis. 
Spoj za upotrebu prema zahtjevu 3, naznačen time da poremećaj ili bolest je osteoartritis.
A kit according to example 31, wherein the material is selected from the group consisting of silicone, hyaluronic acid, polyacrylamide hydrogel, soya, alginates such as modified alginates, bacterial polysaccharides such as gellan gum, plant polysaccharides such as carrageenans, hyaluronic acids, polyethylene oxide-polypropylene glycol block copolymers, proteins such as fibrin, collagen, and gelatin, mixtures of polyethylene oxide and polyacrylic acid, cross-linked chitosan, photochemically cross-linked ethylenically unsaturated groups, macromers such as PEG-oligolactyl-acrylates, polyethylenimine, poly-lysine, poly(vinylamine), and poly(allylamine). 
Oprema u skladu s patentnim zahtjevom 30, kod koje je materijal odabran iz skupine koju čine silikon, hijaluronska kiselina, poliakrilamid hidrogel, soja, alginati kao što su modificirani alginati, bakterijski polisaharidi kao što je želatinska guma, biljni polisaharidi kao što su karagenani, hijaluronske kiseline, polietilen oksid-polipropilen glikol blok polimeri, proteini kao što su fibrin, kolagen i želatina, smjese polietilen oksida i poliakrilne kiseline, umreženi kitozan, fotokemijski umrežene etilenske nezasićene skupine, makromeri kao što su PEG-oligolaktil-akrilati, polietilenimin, polilizin, poli(vinilamin) i polialilamin).
The conjugate according to claim 1, wherein the conjugate has anti-obesity effects. 
Konjugat prema bilo kojem od zahtjeva 1 do 6, naznačen time da konjugat ima učinak protiv pretilosti.
The method of claim 7, wherein the variable regions of the 1st and the 2nd antibody heavy chains recognize different target epitopes, whereas the variable regions of the 3rd and the 4th antibody heavy chains recognize the same target epitopes. 
Postupak u skladu patentnim zahtjevom 7, naznačen time što varijabilne regije prvog i drugog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju različite ciljne epitope, pri čemu varijabilne regije trećeg i četvrtog polipeptidnog lanca koji sadrže CH3 domenu prepoznaju iste ciljne epitope.
A process for preparing an EC formulation, comprising the steps of mixing components a, b, c and optionally d according to any one of claims 1 to 9 if appropriate with stirring and/or heating. 
Postupak za pripremu formulacije koncentrata za emulziju, naznačen time što sadrži korake miješanja komponenti a, b, ci izborno d, prema bilo kojem od patentnih zahtjeva I do 9, ako je pogodno uz miješanje i/ili zagrijavanje.
microfluidizing the first emulsion to form a second emulsion having a second average oil droplet size which is less than the first average oil droplet size, wherein the microfluidizing occurs in an interaction chamber that provides a shear rate >2.5×106 s−1. 
Postupak prema bilo kojem od prethodnih zahtjeva koji sadrži: (1i) mikrofluidizaciju prve emulzije da bi se formirala druga emulzija koja ima drugu prosječnu veličinu kapljica ulja koja je manja od prve prosječne veličine kapljica ulja.
Therefore, in a preferred embodiment the increase in the signal mediated by the CB1 cannabinoid receptor involves modifying said neural stem cell to increase the expression of the CB1 cannabinoid receptor above basal levels. 
(ii) uvođenje u navedenu neuralnu matičnu stanicu ekspresijskog vektora koji kodira kanabinoidni receptor CB, kako bi se povećalo eksprimiranje kanabinoidnog receptora CB; iznad osnovne razine, i/ili
The method of claim 41, wherein the cancer exhibits overexpression, translocation, amplification, or rearrangement of a myc family oncoprotein and is selected from B-acute lymphocytic leukemia, Burkitt's lymphoma, Diffuse large cell lymphoma, Multiple myeloma. 
Spoj ili pripravak za uporabu prema patentnom zahtjevu 31, naznačen time, da karcinom je povezan s prekomjernom ekspresijom, translokacijom, amplifikacijom, ili rearanžmanom onkoproteina obitelji myc koji je osjetljiv na inhibiciju BET;
The system of claim 5 wherein the electric heater has a maximum dimension perpendicular to its length that varies. 
Sustav (10) prema zahtjevu 5, pri čemu električni grijač (14) ima vertikalnu dimenziju u odnosu na njegovu dužinu, koja varira.
The formulation in the form of an oil dispersion of claim 1, comprising to 10% by weight of the iodosulfuron-methyl sodium salt, 
Formulacija u obliku uljne disperzije prema zahtjevu 1, naznačena time da sadrži
Procedure for the preparation of naphthalene derivatives of structure I, according to claims 1 and 2, that carry in R1 an acid or amino terminal group characterized by the reaction of the acylating agent, N -hydroxysuccinimide ester of 4-(1-naphthylamino)-4-oxobutanoic acid of claim 4, with compounds having primary amino groups, such as aliphatic diamines, linear or branched, and polyfunctional amines such as a-amino acids, thioamines, aminoalcohols and aminocarboxylic acids, in presence or not of an organic base, in DMF or 1,4-dioxane as solvent. 
Postupak za pripremu derivata naftalena strukture I, prema zahtjevima 1 i 2, koji u Ry nose neku kiselinsku ili amino terminalnu skupinu, naznačen reakcijom acilacijskog sredstva, N-hidroksisukcinamid estera 4-(1- naftalimino)-4-oksobutanoične kiseline prema zahtjevu 4, pri čemu spojevi imaju primarne amino skupine kao što su alifatski diamini, linearni ili razgranati, i polifunkcionalne amine kao što su a-amino kiseline, tioamini, aminoalkoholi i aminokarboksilne kiseline, u prisutnosti neke organske baze ili bez nje, u DMF-u ili 1,4-dioksanu kao otapalu.
In other embodiments, the present invention relates to a product or composition comprising methimazole, pilocarpine and two additional active compounds, preferably mifepristone and sorbitol. 
Sastav u skladu s bilo kojim od patentnih zahtjeva 1 do 9, koji obuhvaća metimazol, pilokarpin, baklofen, mifepriston i sorbitol.
The present invention is directed to crystallized polyethylene terephthalate, PET, which contains silicon bounded and integrated into the molecular structure of PET form. 
Ovaj je izum usmjeren na kristalizirani polietilen tereftalat, PET, koji sadrži silikon u obliku vezanom i integriranom u molekulsku strukturu PET-a.
Suitable binders and adhesives include, but are not limited to acacia gum, guar gum, tragacanth gum, sucrose, gelatin, glucose, starch, and cellulosics (i.e. methylcellulose, sodium carboxymethylcellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, and the like), water soluble or dispersible binders (i.e. alginic acid and salts thereof, magnesium aluminum silicate, hydroxyethylcellulose [i.e. TYLOSE™ available from Hoechst Celanese], polyethylene glycol, polysaccharide acids, bentonites, polyvinylpyrrolidone, polymethacrylates and pregelatinized starch) and the like. 
Farmaceutska dozna formulacija prema patentnom zahtjevu 5, naznačena time što su vezivo i adheziv izabrani iz grupe koju čine akacija guma; guar guma; tragakant guma; saharoza; želatin; glukoza; škrob; celuloze kao što su metilceluloza, natrij karboksimetilceluloza, etilceluloza, hidroksipropilmetilceluloza, hidroksipropilceluloza; i u vodi topljiva ili disperzibilna veziva kao što je alginska kiselina i njene soli, magnezij aluminij silikat, hidroksietilceluloza, polietilen glikol, polisaharidne kiseline, bentoniti, polivinilpirolidon, polimetakrilati, i preželatinizirani škrob.
Unhooking from a Mooring Buoy The user places the control levers in their neutral positions, and activates the system as described above. 
6. -Odvezivanje od sidrene plutače Korisnik postavlja upravljačke kontrole u njihov neutralni položaj te aktivira sustav kao što je gore opisano.
The mixture may, for example, be formed into tablets by direct tabletting. 
Primjerice, smjesa se može oblikovati u tablete izravnim tabletiranjem.
The formulation of claim 1, wherein the formulation has an SPF of at least 40. 
Pripravak prema zahtjevu 1, gdje pripravak ima SPF najmanje 40.
The round-bottom flask and the solid were washed with water (2×50 ml) and all the washing aqueous fractions were combined, then concentrated under vacuum (40 ml). 
Okrugla tikvica 1 krutina su prane vodom (2 x 50 mL) i frakcije od pranja su spojene i uparavane pod vakuumom (40 mL).
the adjuster includes an adjuster mandrel that is rotatable relative to the hollow housing and has an external portion that is engageable from outside the hollow housing via a side thereof, and an adjuster portion that is threadedly connected to the jar mandrel such that rotation of the adjuster mandrel relative to the jar mandrel alters the length of the chamber and hence the degree of compression of the compression spring. 
- = podešivač sadrži vreteno (47) podešivača, koji se može okretati u odnosu na šuplje kućište i ima vanjski dio (49) koji je zahvaćen izvan šupljeg kućišta preko boka kućišta, i dio (51) podešivača, koji je navojem povezan za vreteno udaraca, tako da okretanje vretena podešivača u odnosu na vreteno udaraca mijenja dužinu komore 1 time stupanj sabijanja kompresijske opruge, i
A process for the preparation of a compound represented by formula (V): comprising the steps of: 
PATENTNI ZAHTJEVI 1. = Postupak za pripremu spoja predstavljenog formulom (V):
The medicament for use according to claim 1 or 2, wherein the a-synuclein-related disorder is selected from the group consisting of Parkinson's disease, dementia with Lewy bodies and/or Lewy neurites, Alzheimer's disease, Down's syndrome, Multiple Systemic Atrophy (MSA), other diseases with Lewy body pathology, and Alzheimer's disease syndrome. 
Lijek za uporabu prema zahtjevu 1 ili 2, pri čemu je poremećaj vezan uz a-sinuklein odabran iz skupine koja se sastoji od Parkinsonove bolesti, demencije s Lewyjevim tjelešcima i/ili Lewyjevim neuritima, Alzheimerove bolesti, Downovog sindroma, multiple sistemske atrofije (MSA), drugih bolesti s patologijom Lewyjevih tjelešaca i sindroma Alzheimerove bolesti.
In the proximity of the end 55 there are two opposing rounded raised sections 56 in the form of bosses, intended to engage the slots 29 of the housings 24 in order to comprise a temporary mechanical catch, suitable for developing a stiff whole before the recoil impulse. 
U blizini kraja 55 nalaze se na suprotnim stranama dvije uzdignute sekcije 56 u obliku čepova koji su namijenjeni da se zahvate u utore 29 kućišta 24, da bi se na taj način dobilo mehaničko zahvaćanje koje je potrebno za stvaranje ukupnog ukrućenja prije impulsa trzanja.
A single-layer printing method according to claim 6, characterized in that the combustion agent is selected from the group of organic acid salts, preferably citric, maleic, lactic, acetic and tartaric acids and mixtures thereof. 
Postupak jednoslojnog tiska prema Zahtjevu 9, naznačen time, što je agens za sagorijevanje sol organske kiseline koja je odabrana iz grupe koja obuhvaća limunske, maleinske, mliiečne, octene i vinske kiseline ili njihove mješavine.
A pharmaceutical composition for use in treating a cancer with cancer cells or tumours that are CD47+, preferably wherein the cancer is a hematological cancer, preferably human acute myeloid leukemia (AML), comprising an effective amount of a polypeptide and a pharmaceutically acceptable carrier, the polypeptide selected from the group consisting of: 
Farmaceutski sastav za uporabu u liječenju maligniteta s tumorskim stanicama koje su CD47+, obuhvaća efektivnu količinu tvari kako je definirano u bilo kojem od patentnih zahtjeva 1-12 i 17 i farmaceutski prihvatljivi nosač. Farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 18, pri čemu je malignitet hematološki malignitet.
A compound, pharmaceutically acceptable salt thereof or composition according to claim 4, for use in treatment of neuropathic pain or pseudobulbar affect. 
Tvar, njena farmaceutski prihvatljiva sol ili sastav prema patentnom zahtjevu 8, za uporabu u liječenju neuropatske boli ili pseudobulbarnog afekta.
A nitrogen atom within a heterocyclyl group may be oxidized to give the corresponding N oxide. 
Dušikov atom unutar heterocikličke skupine može biti oksidiran, čime se dobije odgovarajući N-oksid.
Use according to any of the preceding items, wherein the one or more oligomers of lactic acid release lactic acid over a time period of at least 8 hours, at least 12 hours, such as at least 16 hours, at least 20 hours, at least 24 hours, at least 36 hours, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, or at least 7 days when exposed to water at room temperature. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu jedan ili više oligomera mliječne kiseline otpuštaju mliječnu kiselinu kroz vremenski period od barem 8 sati, barem 12 sati, kao barem 16 sati, barem 20 sati, barem 24 sata, barem 36 sati, barem 2 dana, barem 3 dana, barem 4 dana, barem 5 dana, barem 6 dana, ili barem 7 dana kada su izloženi vodi pri sobnoj temperaturi.